{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:41:20Z","timestamp":1789875680601,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal des Maladies Vasculaires"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jmv.2014.04.002","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T13:04:39Z","timestamp":1401714279000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin\u00a0K antagonists"],"prefix":"10.1016","volume":"39","author":[{"given":"J.","family":"B\u00e9n\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-E.","family":"Dubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Senis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Auffret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmv.2014.04.002_bib0005","first-page":"3","article-title":"Prise en charge des surdosages en antivitamines K\u00a0: \u00e0 propos d\u2019une enqu\u00eate observationnelle aupr\u00e8s de 70\u00a0\u00e9tablissements hospitaliers fran\u00e7ais","volume":"54","author":"Si\u00e9","year":"2002","journal-title":"Urgence Pratique"},{"key":"10.1016\/j.jmv.2014.04.002_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820\u00a0patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jmv.2014.04.002_bib0170","unstructured":"ANSM. Etudes et enqu\u00eates sur les AVK. [Internet]. Accessed 31 July, 2013. Available at: http:\/\/ansm.sante.fr\/Dossiers\/Anti-vitamine-K-AVK\/Etudes-et-enquetes-sur-les-AVK\/(offset)\/4."},{"key":"10.1016\/j.jmv.2014.04.002_bib0020","unstructured":"ANSM. Les Matin\u00e9es avec la Presse, 25 septembre 2008 [Internet]. Accessed 31 July 2013. Available at: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/EMIR.pdf."},{"key":"10.1016\/j.jmv.2014.04.002_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0030","unstructured":"HAS. Octaplex. Avis de la Commission de Transparence. 22 juin 2005. [internet] Accessed July 31, 2013. Available at: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/ct031904.pdf."},{"key":"10.1016\/j.jmv.2014.04.002_bib0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2014.04.002_bib0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4065\/70.8.725","article-title":"Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota","volume":"70","author":"Gitter","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jmv.2014.04.002_bib0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0060","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2014.04.002_bib0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2014.04.002_bib0070","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3months of anticoagulant therapy","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0075","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2014.04.002_bib0080","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmv.2014.04.002_bib0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation. A multicenter study","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0090","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","article-title":"Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis","volume":"126","author":"Reynolds","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2014.04.002_bib0095","doi-asserted-by":"crossref","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633\u20138.","DOI":"10.1016\/S0140-6736(96)03487-3"},{"key":"10.1016\/j.jmv.2014.04.002_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pharma.2009.11.003","article-title":"Which factors are associated to hemorrhagic adverse drug events related to antivitamin\u00a0K?","volume":"68","author":"Al Hajje","year":"2010","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.jmv.2014.04.002_bib0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejvs.2005.03.005","article-title":"Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study","volume":"30","author":"Ariesen","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jmv.2014.04.002_bib0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2796.1989.tb00053.x","article-title":"Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis","volume":"225","author":"Lundstr\u00f6m","year":"1989","journal-title":"J Intern Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0002-9343(99)00267-3","article-title":"Major bleeding after hospitalization for deep-venous thrombosis","volume":"107","author":"White","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2014.04.002_bib0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002512-199914040-00005","article-title":"Safety of treatment with oral anticoagulants in the elderly. A systematic review","volume":"14","author":"Hutten","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jmv.2014.04.002_bib0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0028-3770(09)73174-1","article-title":"Prognosis factors of oral-anticoagulant-related intracranial haemorrhages: an analysis of 186\u00a0cases","volume":"55","author":"Colnat-Coulbois","year":"2009","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.jmv.2014.04.002_bib0135","doi-asserted-by":"crossref","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2014.04.002_bib0140","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2012.05.008","article-title":"Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation","volume":"34","author":"Suh","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jmv.2014.04.002_bib0145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/07853890903186168","article-title":"The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients","volume":"41","author":"Hauta-Aho","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0150","first-page":"640","article-title":"Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions","volume":"12","author":"Zhang","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jmv.2014.04.002_bib0155","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.04.002_bib0160","first-page":"413743","article-title":"Warfarin dosing in a patient with CYP2C9(*)3(*)3 and VKORC1-1639 AA genotypes","volume":"2014","author":"Johnson","year":"2014","journal-title":"Case Rep Genet"},{"key":"10.1016\/j.jmv.2014.04.002_bib0165","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/j.ijcard.2013.07.151","article-title":"Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis","volume":"168","author":"Yang","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["Journal des Maladies Vasculaires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049914000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049914000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:13:32Z","timestamp":1759954412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0398049914000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0398049914000584"],"URL":"https:\/\/doi.org\/10.1016\/j.jmv.2014.04.002","relation":{},"ISSN":["0398-0499"],"issn-type":[{"value":"0398-0499","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin\u00a0K antagonists","name":"articletitle","label":"Article Title"},{"value":"Journal des Maladies Vasculaires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmv.2014.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}